top of page


CHMP recommends Innovent's Zybrivo sintilimab for first-line non-squamous lung cancer in Europe
The EMA's CHMP has recommended Innovent's Zybrivo, containing sintilimab, for first-line treatment of eligible patients with non-squamous non-small cell lung cancer, advancing the immunotherapy towards a potential European marketing authorisation.

nuaxia
1 day ago2 min read


FDA declines approval of Summit and Akeso's ivonescimab for EGFR-mutated lung cancer
The FDA has issued a Complete Response Letter for Summit Therapeutics' ivonescimab in EGFR-mutated lung cancer after the HARMONi trial demonstrated a progression-free survival benefit but did not establish a statistically significant overall-survival benefit.

nuaxia
1 day ago2 min read
bottom of page